I am a research associate professor with the Tufts Center for the Study of Drug Development. As a health economist, my research areas concern prescription drug policy, and specifically pricing and reimbursement of newly approved biopharmaceuticals. In turn, I analyze market or patient access to biopharmaceuticals, in the U.S. and globally. I examine drug approvals by regulatory agencies, such as the Food and Drug Administration. Subsequently, I analyze how patients gain access to newly approved products: out-of-pocket, through insurers, or by way of patient assistance programs funded by the pharmaceutical industry, philanthropies, and governments. In my research, I have focused on understanding the ways in which insurers evaluate new approvals to establish which ones get covered, how much the patient pays out-of-pocket, and which conditions are applied to coverage.